|
1
|
Fuller GN and Scheithauer BW: The 2007
Revised World Health Organization (WHO) Classification of Tumours
of the Central Nervous System: Newly codified entities. Brain
Pathol. 17:304–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng H, Liu KW, Guo P, Zhang P, Cheng T,
McNiven MA, Johnson GR, Hu B and Cheng SY: Dynamin 2 mediates
PDGFRα-SHP-2-promoted glioblastoma growth and invasion. Oncogene.
31:2691–2702. 2012. View Article : Google Scholar
|
|
4
|
Helseth R, Helseth E, Johannesen TB,
Langberg CW, Lote K, Rønning P, Scheie D, Vik A and Meling TR:
Overall survival, prognostic factors, and repeated surgery in a
consecutive series of 516 patients with glioblastoma multiforme.
Acta Neurol Scand. 122:159–167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guryanova OA, Wu Q, Cheng L, Lathia JD,
Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM,
et al: Nonreceptor tyrosine kinase BMX maintains self-renewal and
tumorigenic potential of glioblastoma stem cells by activating
STAT3. Cancer Cell. 19:498–511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liebelt BD, Shingu T, Zhou X, Ren J, Shin
SA and Hu J: Glioma stem cells: Signaling, microenvironment, and
therapy. Stem Cells Int. 2016:78498902016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li
Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem
cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 66:7843–7848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z, Bao S, Wu Q, Wang H, Eyler C,
Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al:
Hypoxia-inducible factors regulate tumorigenic capacity of glioma
stem cells. Cancer Cell. 15:501–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peñuelas S, Anido J, Prieto-Sánchez RM,
Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo
J, Baselga J, et al: TGF-beta increases glioma-initiating cell
self-renewal through the induction of LIF in human glioblastoma.
Cancer Cell. 15:315–327. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Donaldson KM, Yin H, Gekakis N, Supek F
and Joazeiro CA: Ubiquitin signals protein trafficking via
interaction with a novel ubiquitin binding domain in the membrane
fusion regulator, Vps9p. Curr Biol. 13:258–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Man J and Zhang X: CUEDC2: An emerging key
player in inflammation and tumorigenesis. Protein Cell. 2:699–703.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao YF, Li T, Chang Y, Wang YB, Zhang WN,
Li WH, He K, Mu R, Zhen C, Man JH, et al: Cdk1-phosphorylated
CUEDC2 promotes spindle checkpoint inactivation and chromosomal
instability. Nat Cell Biol. 13:924–933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang WN, Zhou J, Zhou T, Li AL, Wang N,
Xu JJ, Chang Y, Man JH, Pan X, Li T, et al:
Phosphorylation-triggered CUEDC2 degradation promotes UV-induced G1
arrest through APC/CCdh1 regulation. Proc Natl Acad Sci
USA. 110:11017–11022. 2013. View Article : Google Scholar
|
|
15
|
Li HY, Liu H, Wang CH, Zhang JY, Man JH,
Gao YF, Zhang PJ, Li WH, Zhao J, Pan X, et al: Deactivation of the
kinase IKK by CUEDC2 through recruitment of the phosphatase PP1.
Nat Immunol. 9:533–541. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao
Y, Chen Y, Zhang PJ, Yu M, Zhen C, et al: Elevated expression of
CUEDC2 protein confers endocrine resistance in breast cancer. Nat
Med. 17:708–714. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang PJ, Zhao J, Li HY, Man JH, He K,
Zhou T, Pan X, Li AL, Gong WL, Jin BF, et al: CUE domain containing
2 regulates degradation of progesterone receptor by
ubiquitin-proteasome. EMBO J. 26:1831–1842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang S, Pu J, Li N, Li C, Li C, Yu L, Wang
X, Fu S and Cui L: CUEDC2 protects against experimental colitis and
suppresses excessive proliferation of intestinal mucosa. Dig Dis
Sci. 60:3603–3609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun L, Bai L, Lin G, Wang R, Liu Y, Cai J,
Guo Y, Zhu Z and Xie C: CUEDC2 down-regulation is associated with
tumor growth and poor prognosis in lung adenocarcinoma. Oncotarget.
6:20685–20696. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Chang G, Wang J, Lin Y, Ma L and
Pang T: CUEDC2 sensitizes chronic myeloid leukemic cells to
imatinib treatment. Leuk Res. 37:1583–1591. 2013h. View Article : Google Scholar
|
|
21
|
Zhang WN, Wang L, Wang Q, Luo X, Fang DF,
Chen Y, Pan X, Man JH, Xia Q, Jin BF, et al: CUEDC2 (CUE
domain-containing 2) and SOCS3 (suppressors of cytokine signaling
3) cooperate to negatively regulate Janus kinase 1/signal
transducers and activators of transcription 3 signaling. J Biol
Chem. 287:382–392. 2012. View Article : Google Scholar :
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tu Y, Zhong Y, Fu J, Cao Y, Fu G, Tian X
and Wang B: Activation of JAK/STAT signal pathway predicts poor
prognosis of patients with gliomas. Med Oncol. 28:15–23. 2011.
View Article : Google Scholar
|
|
24
|
Phillips HS, Kharbanda S, Chen R, Forrest
WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et
al: Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Collins VP: Mechanisms of disease: Genetic
predictors of response to treatment in brain tumors. Nat Clin Pract
Oncol. 4:362–374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shih SC, Prag G, Francis SA, Sutanto MA,
Hurley JH and Hicke L: A ubiquitin-binding motif required for
intramolecular monoubiquitylation, the CUE domain. EMBO J.
22:1273–1281. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carro MS, Lim WK, Alvarez MJ, Bollo RJ,
Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al:
The transcriptional network for mesenchymal transformation of brain
tumours. Nature. 463:318–325. 2010. View Article : Google Scholar
|
|
28
|
Osugi T, Oshima Y, Fujio Y, Funamoto M,
Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, et
al: Cardiac-specific activation of signal transducer and activator
of transcription 3 promotes vascular formation in the heart. J Biol
Chem. 277:6676–6681. 2002. View Article : Google Scholar
|
|
29
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee H, Deng J, Kujawski M, Yang C, Liu Y,
Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al:
STAT3-induced S1PR1 expression is crucial for persistent STAT3
activation in tumors. Nat Med. 16:1421–1428. 2010. View Article : Google Scholar : PubMed/NCBI
|
